Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
The use of viruses for tumour treatment has been imagined more than one hundred years ago, when it was reported that viral diseases were occasionally leading to a decrease in neoplastic lesions. Oncolytic viruses (OVs) seem to have a specific tropism for tumour cells. Previously, it was hypothesised...
Main Authors: | Vanessa Innao, Vincenzo Rizzo, Andrea Gaetano Allegra, Caterina Musolino, Alessandro Allegra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/28/1/19 |
Similar Items
-
Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies
by: Andrea Gaetano Allegra, et al.
Published: (2020-11-01) -
New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges
by: Alessandro Allegra, et al.
Published: (2021-04-01) -
Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
by: Vanessa Innao, et al.
Published: (2021-02-01) -
Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
by: Valentina Marchica, et al.
Published: (2021-02-01) -
Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia
by: Alessandro Allegra, et al.
Published: (2021-10-01)